Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis ; volume:22 ; number:1 ; day:12 ; month:3 ; year:2020 ; pages:1-8 ; date:12.2020
Arthritis Research & Therapy ; 22, Heft 1 (12.3.2020), 1-8, 12.2020
- Creator
-
Yokoyama-Kokuryo, Waka
Yamazaki, Hayato
Takeuchi, Tsutomu
Amano, Koichi
Kikuchi, Jun
Kondo, Tsuneo
Nakamura, Seiji
Sakai, Ryoko
Hirano, Fumio
Nanki, Toshihiro
Koike, Ryuji
Harigai, Masayoshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-020-2137-y
- URN
-
urn:nbn:de:101:1-2020060405485732511298
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yokoyama-Kokuryo, Waka
- Yamazaki, Hayato
- Takeuchi, Tsutomu
- Amano, Koichi
- Kikuchi, Jun
- Kondo, Tsuneo
- Nakamura, Seiji
- Sakai, Ryoko
- Hirano, Fumio
- Nanki, Toshihiro
- Koike, Ryuji
- Harigai, Masayoshi
- SpringerLink (Online service)
Other Objects (12)
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity